WHAT IS SCINTIMAMMOGRAPHY (MIRALUMA, SESTAMIBI BREAST IMAGING, RADIONUCLIDE BREAST IMAGING) TEST?
A nuclear medicine planar scan in which a radioisotope, technetium-99m sestamibi (Miraluma, 99mTc-sestamibi, 99mTc-MIBI), is used to provide pictures of breast lesions. A “trace” amount of the radioisotope (producing a low dose of radiation) is injected intravenously and accumulates in areas of increased metabolic activity, such as that found in malignant cells. Images of each breast are taken by a gamma (Anger) camera to identify any areas of focal uptake of the isotope, indicating the possible presence of a cancerous lesion. A high-resolution method of this procedure has been shown to be more sensitive than a conventional camera for differentiating indeterminate breast lesions but is still inferior to biopsy. However, this test has a high negative predictive value (93%), making it valuable in reducing the number of negative breast biopsies. Sensitivity is 87.8%, specificity 92.8% and positive predictive value 96.6%.